Insider Transactions in Q1 2022 at Harrow Health, Inc. (HROW)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2022
|
John P. Saharek CEO of ImprimisRx |
SELL
Payment of exercise price or tax liability
|
Direct |
25,923
-32.4%
|
$181,461
$7.87 P/Share
|
|
Feb 19
2022
|
John P. Saharek CEO of ImprimisRx |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+38.46%
|
-
|
|
Feb 19
2022
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
20,605
-7.54%
|
$144,235
$7.87 P/Share
|
|
Feb 19
2022
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+15.47%
|
-
|
|
Jan 28
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
6,343
+0.52%
|
$38,058
$6.89 P/Share
|
|
Jan 20
2022
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
71,406
-4.83%
|
$571,248
$8.33 P/Share
|
|
Jan 20
2022
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+7.8%
|
$250,000
$2.4 P/Share
|